专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2021207161A1 NON-INVASIVE FOCUSED ULTRASOUND NEUROMODULATION TO TREAT PHYSIOLOGICAL CONDITIONS 审中-公开
公开(公告)号：WO2021207161A1
公开(公告)日：2021-10-14
申请号：PCT/US2021/025922
申请日：2021-04-06
申请人： GENERAL ELECTRIC COMPANY , ALBANY MEDICAL COLLEGE
发明人： PULEO, Christopher Michael , COTERO, Victoria Eugenia , KAO, Tzu-Jen , ASHE, Jeffrey Michael , SHIN, Damian Seyung-Ho
IPC分类号： A61N7/02 , A61B8/08
摘要： The subject matter of the present disclosure generally relates to techniques for applying focused ultrasound energy to a region of interest in a subject to induce neuromodulation of the celiac plexus to treat inflammatory bowel disease. The region of interest may include at least a portion of a peripheral ganglion of the celiac plexus.

2. 发明申请

WO2020154138A1 SYSTEMS AND METHODS FOR PREDICTING OPTIMAL DEEP BRAIN STIMULATION PARAMETERS 审中-公开
公开(公告)号：WO2020154138A1
公开(公告)日：2020-07-30
申请号：PCT/US2020/013589
申请日：2020-01-15
申请人： GENERAL ELECTRIC COMPANY , ALBANY MEDICAL COLLEGE
发明人： MADHAVAN, Radhika , ASHE, Jeffrey , JOEL, Suresh , HANCU, Ileana , PILITSIS, Julie , DIMARZIO, Marisa
IPC分类号： A61N1/05 , A61N1/36 , A61B5/055 , A61N1/372 , G01R33/48 , G16H50/70
摘要： A system and method for optimizing parameters of a DBS pulse signal for treatment of a patient is provided. In predicting optimal DBS parameters, functional brain data is input into a predictor system (1), the functional brain data acquired responsive to a sweeping across a multi-dimensional parameter space of one or more DBS parameters. Statistical metrics of brain response are extracted from the functional brain data for one or more ROIs or voxels of the brain via the predictor system (1), and a DBS functional atlas is accessed, via the predictor system (1), that comprises disease-specific brain response maps derived from DBS treatment at optimal DBS parameter settings for a plurality of diseases or neurological conditions. One or more optimal DBS parameters are predicted for the patient based on the statistical metrics of brain response and the DBS functional atlas via the predictor system (1).

3. 发明申请

WO2018106849A1 EX VIVO ANTIGEN AND ADJUVANT PULSED PERIPHERAL BLOOD MONONUCLEAR CELLS AS A SCREENING PLATFORM FOR CANDIDATE NOVEL VACCINES AND CANDIDATE ANTIGENS 审中-公开
公开(公告)号：WO2018106849A1
公开(公告)日：2018-06-14
申请号：PCT/US2017/064989
申请日：2017-12-07
申请人： ALBANY MEDICAL COLLEGE
发明人： GOSSELIN, Edmund J. , KUMAR, Sudeep , NALIN, David
IPC分类号： C07H21/04 , C07K16/28 , C12N5/0784 , C12N15/00 , C12N15/63 , C12N15/86
摘要： Peripheral blood mononuclear cells (PBMCs) can be used in place of DCs when pulsing with antigens, or antigen and adjuvant combination, and then administered to a subject as a vaccine to induce a protective immune response. The PBMC-based vaccine strategy provides a more marked and enduring protective immune response and is also capable of serving as a multi-organism prophylactic vaccine platform. The vaccine platform may be used to screen vaccine and adjuvant combinations and may also be used to allow for adjuvants that are otherwise unsafe for use in humans as the adjuvant may be removed prior to prophylactic administration of the pulsed PBMCs.

4. 发明申请

WO2011088462A3 ALPHA-FETOPROTEIN 'RING AND TAIL' PEPTIDES 审中-公开
公开(公告)号：WO2011088462A3
公开(公告)日：2011-07-21
申请号：PCT/US2011/021560
申请日：2011-01-18
申请人： ALBANY MEDICAL COLLEGE , ANDERSEN, Thomas, T. , JACOBSON, Herbert I. , BENNETT, James A. , JOSEPH, Leroy , BRYAN, Alberto
发明人： ANDERSEN, Thomas, T. , JACOBSON, Herbert I. , BENNETT, James A. , JOSEPH, Leroy , BRYAN, Alberto
IPC分类号： C07K7/52 , A61K38/12 , A61P35/00
摘要： The invention relates to compounds that are analogs of a cyclic peptide, cyclo [EKTOVNOGN], AFPep, that has anti-estrotrophic activity. The analogs of the invention include peptides and petidomimetics that inhibit estrogen receptor dependent cell proliferation. The compounds of the invention are useful for treating cell proliferative disorders or physiological conditions characterized by undesirable or unwanted estrogen induced cell proliferation, including breast cancer.

5. 发明申请

WO2008089392A3 ATTENUATED VACCINE FOR TULAREMIA 审中-公开
标题翻译：用于TULAREMIA的灭菌疫苗
公开(公告)号：WO2008089392A3
公开(公告)日：2008-11-27
申请号：PCT/US2008051411
申请日：2008-01-18
申请人： UNIV SOUTH FLORIDA , ALBANY MEDICAL COLLEGE , BAY PINES VA HEALTHCARE SYSTEM , ANDERSON BURT , CITRON JEAN , SAMMONS WENDY , BAKSHI CHANDRA SHEKHAR , METZGER DENNIS
发明人： ANDERSON BURT , CITRON JEAN , SAMMONS WENDY , BAKSHI CHANDRA SHEKHAR , METZGER DENNIS
IPC分类号： A61K39/02 , A01N63/00
CPC分类号： A61K39/0208 , A61K2039/522
摘要： A scan of F. tularensis genome for homology to a regulatory protein that controls virulence identified gene FTL0552. A knock out mutation in FTL0552 was created using reverse transcriptase PCR and the construct inserted into F. tularensis. This mutant was defective for survival in macrophages and found avirulent in in vivo testing, where the FTL0552 mutant exhibited reduced levels of pro-inflammatory cytokine production, reduced evidence of histopathology in affected tissues, reduced systemic infection, and rapid clearance of the bacterium. In vivo challenge studies with the FTL0552 mutant using the virulent F. tularensis subsp. tularensis SchuS4 strain show an immune response is induced, and protection afforded, after preexposure to the FTL0552 mutant. Microarray studies revealed 148 genes regulated by FTL0552, including genes located within the FPI that are essential for intracellular survival.
摘要翻译：与控制毒力鉴定基因FTL0552的调节蛋白的同源性的土拉曼氏弧菌基因组的扫描。使用逆转录酶PCR产生FTL0552中的敲除突变，并将该构建体插入到土拉氏木霉中。该突变体在巨噬细胞中存活有缺陷并且在体内测试中无毒，其中FTL0552突变体表现出降低的促炎细胞因子产生水平，减少受影响组织中组织病理学的证据，减少的全身感染和细菌的快速清除。使用FTL0552突变体的体内攻击研究，使用毒力土壤杆菌亚种土拉氏SchuS4菌株显示免疫反应被诱导，并且在暴露于FTL0552突变体后得到保护。微阵列研究揭示了由FTL0552调控的148个基因，包括FPI内的基因对细胞内存活必不可少的基因。

6. 发明申请

WO2002072872A2 SYSTEM FOR SCREENING FATTY ACID TRANSPORT INHIBITORS, METHODS OF USE AND MODULATORS IDENTIFIED THEREBY 审中-公开
标题翻译：用于筛选脂肪酸运输抑制剂的系统，使用方法和鉴定的调节剂
公开(公告)号：WO2002072872A2
公开(公告)日：2002-09-19
申请号：PCT/US2002/007884
申请日：2002-03-14
申请人： ALBANY MEDICAL COLLEGE , BLACK, Paul , DIRUSSO, Concetta
发明人： BLACK, Paul , DIRUSSO, Concetta
IPC分类号： C12Q
CPC分类号： C12Q1/25 , G01N33/92 , G01N2333/9015 , G01N2800/044
摘要： Methods for identifying modulators of fatty acid transport and/or uptake, comprising contacting, under conditions favorable for fatty acid uptake, a putative modulator, e.g., an inhibitor with a system comprising genetic material encoding a fatty acid transport mediator ("TTM"), particularly FAA1, FAA2, FAA3, FAA4. FAT1, fadL, fadD , FATP, CD36 and FABP, or orthologs, homologs, isoforms, variants, analogs, derivatives or fragments thereof, and combinations thereof, or fatty acid transport mediator proteins ("TTMps"), e.g., Faa1p, Faa2p, Faa3p, Faa4p, Fat1p, FadL, fatty acyl CoA synthetase, FATP, CD36 and FABP, or orthologs, homologs, isoforms, variants, analogs, derivatives or fragments thereof, and combinations thereof, and determining the effect of the putative modulator. The test system may be a cell such as Saccharomyces cerevisiae, E. coli, H. sapiens, etc. or an in vitro system.
摘要翻译：用于鉴定脂肪酸转运和/或摄取的调节剂的方法包括在有利于脂肪酸摄取的条件下，将推定的调节剂例如抑制剂与包含编码脂肪酸转运介体（“TTM”）的遗传物质的系统接触，特别是FAA1，FAA2，FAA3，FAA4。 FAT1，fadL，fadD，FATP，CD36和FABP，或直系同源物，同系物，同种型，变体，类似物，衍生物或其片段及其组合，或脂肪酸转运介质蛋白（“TTMps”），例如Faa1p，Faa2p， Faa3p，Faa4p，Fat1p，FadL，脂肪酰辅酶A合成酶，FATP，CD36和FABP，或直系同源物，同系物，同种型，变体，类似物，衍生物或其片段及其组合，并确定推定的调节剂的作用。测试系统可以是细胞，例如酿酒酵母，大肠杆菌，黑麦草等，或体外系统。

7. 发明申请

WO2002068451A3 SPERM PROTEIN 17 FOR THE DIAGNOSIS AND TREATMENT OF CANCER 审中-公开
公开(公告)号：WO2002068451A3
公开(公告)日：2002-09-06
申请号：PCT/US2002/005905
申请日：2002-02-26
申请人： ALBANY MEDICAL COLLEGE
发明人： LIM, Seah, H. , CHIRIVA-INTERNATI, Maurizio , WANG, Zhiqing
IPC分类号： A61K39/395
摘要： The results herein identify Sp17 as a novel cancer-testis antigen in multiple myeloma. Sp17 recombinant protein was generated from E. coli. A CD8 predominant CTL line was generated that was able to lyse autologous targets in a Sp17-dependent HLA class I-restricted manner, using dendritic cells as the antigen-presenting cells and DOTAP to deliver the Sp17 protein to the dedritic cells. A combination of HLA-matched and mismatched antibody-enriched fresh myeloma tumor cells and myeloma cell lines were used as targets for the recombinant protein-propagated CTL. The findings of target cell lysis suggest that the Sp17 protein produced by Sp17 + tumor cells are processed and presented in vivo and that the CTL epitopes are presented in association with HLA class I molecules in a concentration and configuration recognized by recombinant protein-propagated CTL.

8. 发明申请

WO2002068451A2 SPERM PROTEIN 17 FOR THE DIAGNOSIS AND TREATMENT OF CANCER 审中-公开
标题翻译：用于诊断和治疗癌症的SPERM蛋白17
公开(公告)号：WO2002068451A2
公开(公告)日：2002-09-06
申请号：PCT/US2002/005905
申请日：2002-02-26
申请人： ALBANY MEDICAL COLLEGE
发明人： LIM, Seah, H. , CHIRIVA-INTERNATI, Maurizio , WANG, Zhiqing
IPC分类号： C07K
CPC分类号： G01N33/57484 , A61K39/0011 , A61K47/6849 , A61K2039/505 , A61K2039/5152 , A61K2039/5154 , C07K14/4748 , C12Q1/6886 , C12Q2600/158
摘要： The results herein identify Sp17 as a novel cancer-testis antigen in multiple myeloma. Sp17 recombinant protein was generated from E. coli. A CD8 predominant CTL line was generated that was able to lyse autologous targets in a Sp17-dependent HLA class I-restricted manner, using dendritic cells as the antigen-presenting cells and DOTAP to deliver the Sp17 protein to the dedritic cells. A combination of HLA-matched and mismatched antibody-enriched fresh myeloma tumor cells and myeloma cell lines were used as targets for the recombinant protein-propagated CTL. The findings of target cell lysis suggest that the Sp17 protein produced by Sp17 + tumor cells are processed and presented in vivo and that the CTL epitopes are presented in association with HLA class I molecules in a concentration and configuration recognized by recombinant protein-propagated CTL.
摘要翻译：本文的结果将Sp17鉴定为多发性骨髓瘤中的新型癌 - 睾丸抗原。从大肠杆菌中产生Sp17重组蛋白。产生了CD8主要的CTL系，其能够使用树突状细胞作为抗原呈递细胞并以DOTAP将Sp17蛋白递送至德耳细胞细胞，以Sp17依赖性HLA I类限制性方式裂解自体靶。将HLA匹配和错配的抗体富集新鲜骨髓瘤肿瘤细胞和骨髓瘤细胞系的组合用作重组蛋白质繁殖CTL的靶标。靶细胞裂解的发现表明，Sp17 +肿瘤细胞产生的Sp17蛋白在体内被处理和呈递，并且CTL表位与HLA I类分子相关联，其浓度和构型通过重组蛋白质传播 CTL。

9. 发明申请

WO2002060425A1 METHODS AND COMPOSITIONS FOR TREATING ADDICTION DISORDERS 审中-公开
标题翻译：治疗接触性疾病的方法和组合
公开(公告)号：WO2002060425A1
公开(公告)日：2002-08-08
申请号：PCT/US2002/002547
申请日：2002-01-29
申请人： ALBANY MEDICAL COLLEGE
发明人： GLICK, Stanley, D. , MAISONNEUVE, Isabelle, M.
IPC分类号： A61K31/00
CPC分类号： A61K45/06
摘要： A method for treating an addiction disorder (such as an addiction to or dependency on stimulants, nicotine, morphine, heroin, other opiates, amphetamines, cocaine, and/or alcohol) in a patient is disclosed. The method includes administering to the patient a first α 3 β 4 nicotinic receptor antagonist and administering to the patient a second α 3 β 4 nicotinic receptor antagonist. The second α 3 β 4 nicotinic receptor antagonist is different than the first α 3 β 4 nicotinic receptor antagonist and the second α 3 β 4 nicotinic receptor antagonist are administered simultaneously or non-simultaneously. Compositions which include a first α 3 β 4 nicotinic receptor antagonist are also described. Examples of suitable α 3 β 4 nicotinic receptor antagonists for use in the present invention's methods and compositions include mecamylamine, 18-methoxycoronaridine, bupropion, dextromethorphan, dextrorphan, and pharmaceutically acceptable salts and solvates thereof. A method of evaluating a compound for its effectiveness in treating addiction disorders is also described.
摘要翻译：公开了一种治疗患者的成瘾症状（例如成瘾或依赖兴奋剂，尼古丁，吗啡，海洛因，其他阿片剂，苯丙胺，可卡因和/或酒精）的方法。该方法包括向患者施用第一α3β4烟碱受体拮抗剂并向患者施用第二α3β4烟碱受体拮抗剂。第二个α3β4烟碱受体拮抗剂与第一个α3β4烟碱受体拮抗剂不同，第二个α3β4烟碱受体拮抗剂同时或不同时施用。还描述了包含第一α3β4烟碱受体拮抗剂的组合物。用于本发明方法和组合物的合适的α3β4烟碱受体拮抗剂的实例包括美加明，18-甲氧基冠醚，安非他酮，右美沙芬，右美沙芬及其药学上可接受的盐和溶剂合物。还描述了一种评价化合物治疗成瘾症的有效性的方法。

10. 发明申请

WO1998010749A1 PROTEIN-LIPID VESICLES AND AUTOGENOUS VACCINE COMPRISING THE SAME 审中-公开
标题翻译：蛋白脂蛋白和包含其的自动真菌疫苗
公开(公告)号：WO1998010749A1
公开(公告)日：1998-03-19
申请号：PCT/US1997015357
申请日：1997-09-02
申请人： ALBANY MEDICAL COLLEGE , UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
发明人： ALBANY MEDICAL COLLEGE , UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY , OLESKE, James, M. , DENNY, Thomas, N. , SCOLPINO, Anthony, J. , FEKETEOVA, Eleonora , GOULD-FOGERITE, Susan , MANNINO, Raphael, J.
IPC分类号： A61K09/127
CPC分类号： A61K9/1271 , A61K2039/55555 , Y02A50/41 , Y02A50/412 , Y02A50/423 , Y10S424/812 , Y10S436/829
摘要： A protein-lipid vesicle that can be used to make an autogenous vaccine comprises patient-specific antigen, adjuvant or immunomodulator, and lipid carrier. In addition, a negatively charged lipid component is desirably included. The autogenous vaccine is useful to treat individuals with chronic diseases, including chronic infectious diseases and neoplasias. The chronic infectious diseases that can be treated include disease caused by infection with human immunodeficiency viruses.
摘要翻译：可用于制备自体疫苗的蛋白质 - 脂质囊泡包括患者特异性抗原，佐剂或免疫调节剂和脂质载体。此外，期望包括带负电的脂质成分。自体疫苗可用于治疗慢性疾病的个体，包括慢性传染病和肿瘤。可治疗的慢性感染性疾病包括由人体免疫缺陷病毒感染引起的疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式